HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Raitila, A Articles by Aaltonen, L A Search for Related Content PubMed PubMed Citation Articles by Raitila, A Articles by Aaltonen, L A

Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, PO Box 63, Haartmaninkatu 8, FIN-00014 University of Helsinki, Finland
¹ Department of Pathology, University of Oulu, 90014 Oulu, Finland
² Department of Clinical Biochemistry, Aarhus University Hospital/Skejby, 8200 Aarhus, Denmark
³ Department of Pathology, University of Helsinki and HUSLAB, 00014 Helsinki, Finland

(Correspondence should be addressed to L A Aaltonen; Email: lauri.aaltonen{at}helsinki.fi)

Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene were recently observed in patients with pituitary adenoma predisposition (PAP). Though AIP mutation-positive individuals with prolactin-, mixed growth hormone/prolactin-, and ACTH-producing pituitary adenomas as well as non-secreting pituitary adenomas have been reported, most mutation-positive patients have had growth hormone-producing adenomas diagnosed at relatively young age. Pituitary adenomas are also component tumors of some familial endocrine neoplasia syndromes such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Genes underlying MEN1 and CNC are rarely mutated in sporadic pituitary adenomas, but more often in other lesions contributing to these two syndromes. Thus far, the occurrence of somatic AIP mutations has not been studied in endocrine tumors other than pituitary adenomas. Here, we have analyzed 32 pituitary adenomas and 79 other tumors of the endocrine system for somatic AIP mutations by direct sequencing. No somatic mutations were identified. However, two out of nine patients with prolactin-producing adenoma were shown to harbor a Finnish founder mutation (Q14X) with a complete loss of the wild-type allele in the tumors. These results are in agreement with previous studies in that prolactin-producing adenomas are component tumors in PAP. The data also support the previous finding that somatic AIP mutations are not common in pituitary adenomas and suggest that such mutations are rare in other endocrine tumors as well.

This article has been cited by other articles:

				E. Heliovaara, A. Raitila, V. Launonen, A. Paetau, J. Arola, H. Lehtonen, T. Sane, R. J. Weil, O. Vierimaa, P. Salmela, et al. The Expression of AIP-Related Molecules in Elucidation of Cellular Pathways in Pituitary Adenomas Am. J. Pathol., December 1, 2009; 175(6): 2501 - 2507. [Abstract] [Full Text] [PDF]

				S K Khoo, R Pendek, R Nickolov, D C Luccio-Camelo, T L Newton, A Massie, D Petillo, J Menon, D Cameron, B T Teh, et al. Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma Endocr. Relat. Cancer, September 1, 2009; 16(3): 1057 - 1063. [Abstract] [Full Text] [PDF]

				M. Georgitsi, E. Heliovaara, R. Paschke, A. V. K. Kumar, M. Tischkowitz, O. Vierimaa, P. Salmela, T. Sane, E. De Menis, S. Cannavo, et al. Large Genomic Deletions in AIP in Pituitary Adenoma Predisposition J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4146 - 4151. [Abstract] [Full Text] [PDF]